The Three Pillars of MDACS: Device, Trader and Post-Market Listing

1. Key takeaways

MDACS is built on 3 pillars: medical device listing, trader listing covering 4 categories of party (local responsible person, local manufacturer, importer and distributor), and the post-market surveillance system. These are not parallel options on a menu but a chain of dependencies. Without a listed local responsible person (LRP) a device listing application cannot be submitted at all, and without post-market records a listing loses support at renewal and in tender evaluation. Listing the device while neglecting trader listing and post-market duties is the most common structural gap among manufacturers from the Chinese mainland entering Hong Kong, China.

The practical reading is that MDACS is a status held by an entity as much as by a product. Approval letters can carry conditions, and the amendments of 1 September 2026 made that explicit across five guidance notes. A listing is therefore a continuing obligation with a five-year horizon, not a certificate filed away after approval.

The GRZAN view. Where a manufacturer has no Hong Kong, China entity, the LRP appointment is the critical path of the whole project, and it should be signed before any technical file work is commissioned.

2. Legal basis

Guidance notes carry the architecture. GN-01, the Guidance Notes on Overview of the Medical Device Administrative Control System, current version updated and issued on 1 September 2026, sets out the scheme architecture in Chapter 3 and, at paragraph 5.10, the three possible outcomes of an application: refusal, approval, and approval with conditions. Conditions are recorded in the approval letter, and failure to comply can lead to removal from the list. Corresponding provisions appear at paragraph 6.6 of GN-04, paragraph 7.5 of GN-07, paragraph 5.7 of GN-08 and paragraph 4.9 of GN-09. GN-08 at paragraph 5.6.1 fixes the 5-year validity of a local manufacturer listing. GN-03 governs reporting of medical incidents by the local responsible person, and the MDD overview document uploaded on 8 October 2025 describes the post-market surveillance element.

Six public lists form a searchable network. The device list, the local responsible person list, the conformity assessment body list, the importer list, the distributor list and the local manufacturer list are all published on the MDD website. A purchaser can therefore verify a supplier and its products online before award, which gives the accuracy and currency of listing information a publicly testable quality.

3. Expert insights

Trader listing is a precondition, not a companion step. The official process overview is explicit that an applicant must be a local manufacturer, or a local responsible person appointed by the manufacturer, and that the LRP must be a legal person incorporated in Hong Kong, China, or a natural or legal person holding a business registration in the territory. That rule turns the existence of a local entity into a hard threshold for filing, and it is the reason an overseas manufacturer must work through a third-party LRP. Sequencing matters: appointing the LRP after the dossier is drafted usually produces a file that has to be re-signed and re-dated.

The additional conditions introduced on 1 September 2026 changed what approval means. Before the amendment, approval read as an endpoint. Now paragraph 5.10 of GN-01 presents three distinct outcomes, and the middle one, approval with conditions, is the one that catches companies unprepared for obligations attached to the letter rather than to the guidance. Conditions may concern post-market data, changes notification or field safety action. Because non-compliance can lead to removal from the list, the approval letter has to be read as an operating document, with each condition assigned an owner and a date.

Post-market duties sit with the LRP and cannot be outsourced by silence. Handling complaints, reporting adverse events, managing recalls and keeping records are the four duties that sustain a listing. In an arrangement where the manufacturer is offshore, the delegation has to be written: who receives a complaint first, within what interval the manufacturer is informed, and who decides whether an incident is reportable under GN-03. Without those intervals in the agreement, the LRP carries a statutory-flavoured duty with no contractual means of discharging it.

Public lists are a monitoring tool, not just a directory. Because competitors, hospitals and the authority read the same six lists, an out-of-date entry is visible to everyone. A quarterly check is cheap; discovering during a tender that a distributor listing lapsed is not.

4. Practical recommendations

• Entity before dossier. Make LRP selection the first step of any listing plan, complete the appointment and the trader listing, and only then start device-level filing, so the application is not returned on eligibility grounds.
• Read the conditions, not only the approval. After approval, extract each condition from the approval letter into a tracker with an owner, a due date and the evidence that will demonstrate compliance.
• Bind post-market obligations into the listing. Set out in the LRP agreement the four duties, the notification intervals between LRP and manufacturer, and the recall decision route.
• Audit the public lists quarterly. Check the company and product entries in the six MDD lists every quarter and apply for correction where information has fallen behind.
• Map which trader listings apply. A company that both imports and distributes may need two listings, and a contract manufacturer performing local finishing may need a local manufacturer listing.

5. Verification checklist

• □ LRP identified and confirmed as a Hong Kong, China incorporated legal person or holder of a valid business registration.
• □ Importer, distributor or local manufacturer listing assessed against the actual business role.
• □ Additional conditions in the approval letter read and transferred to a compliance tracker.
• □ Four processes in place: complaint handling, adverse event reporting, recall and record keeping.
• □ Company entries verified in the MDD public lists.
• □ Validity period and renewal window confirmed for each listing certificate held.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages Medical Device Administrative Control System (MDACS) listings, coordinates import licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com